#POINT OF CARE, #URGENT CARE
THE IMPACT OF POINT OF CARE TESTING ON URGENT CARE THROUGHPUT
Held December 18, 2025
PACE Credit & Florida CE Credit available until May 18, 2026
Emergency departments are overwhelmed, often managing patients who could be safely treated in urgent care settings if the right diagnostic tools were available. Without point-of-care testing (POCT), urgent care centers may face challenges in rapidly assessing and managing mid-acuity cases, leading to unnecessary ED transfers and longer wait times.
This gap affects both patient outcomes and institutional efficiency. Patients, especially seniors, face delays and overcrowded EDs, while health systems miss opportunities to reduce costs and improve throughput. Expanding the capabilities of urgent care centers may help increase their utilization and ability to alleviate system strain.
#POINT OF CARE, #SEPSIS, #EMERGENCY DEPARTMENT, #LACTATE TESTING
EVOLUTION OF SEPSIS GUIDELINES
Held September 26, 2022
CE has expired.
There is a need for expanded POC lactate testing across EDs for improved sepsis care. Using POCT allows for rapid results from important labs like lactates, which are a critical part of clinical decision-making in the context of sepsis.
#POINT OF CARE, #TROPONIN, #EMERGENCY DEPARTMENT
HOW HIGH SENSITIVITY POC TROPONIN TESTING CAN AID IN AMI DIAGNOSIS
Held July 10, 2025
CE has expired.
Many emergency departments still face challenges in rapidly identifying patients at risk for acute myocardial infarction (AMI), especially in settings where access to central lab testing is limited. While high sensitivity troponin assays are now widely recognized for their diagnostic value, healthcare practitioners continue to adopt varied protocols when using
point of care versions of these assays to support early decision-making in chest pain pathways.
#POINT OF CARE, #hs-TnI ASSAYS, #TROPONIN, #EMERGENCY DEPARTMENT
LET’S TALK TROPONIN:
WHAT YOU NEED TO KNOW ABOUT HIGH-SENSITIVITY TROPONIN ASSAYS
Held April 24, 2025
CE has expired.
Many institutions have not yet adopted high-sensitivity troponin assays in the United States ... even though these assays are now recognized by AHA/ACC as the biomarkers of choice1 in aiding in the diagnosis and disposition for patients with Acute Coronary Syndrome.